The correlation between KLF5/BECN1 levels and prostate cancer prognosis may be helpful toward precision medicine in the clinic by identifying prostate cancer patients, who are more likely to respond to docetaxel treatment. This evidence concerns the gene BECN1 and prostate carcinoma.